IP Library Granted Patent US 9,180,143
Granted Patent B2
US 9,180,143 · App. 14/445,710 · Granted Nov 10, 2015

Decellularisation of tissue matrices for bladder implantation

Inventors: Fiona Bolland (Heslington, GB); Jennifer Southgate (Heslington, GB); Sotirios Korossis (Leeds, GB); Eileen Ingham (Leeds, GB)
Assignee: Tissue Regenix Limited
A61K35/22A61F2/042A61L27/3604A61L27/3679A61L27/3687A61L27/38C12N5/0068G01N33/5088A61L2430/00A61L2430/22A61L2430/40C12N5/0605C12N2509/00C12N2533/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,180,143
App. No.
14/445,710
Granted
Nov 10, 2015
Kind
B2
Abstract

The invention provides an improved method of producing a natural, acellular matrix scaffold for subsequent use in tissue-engineered replacement of tissues such as the bladder. Decellularization is carried out on an expanded or distended bladder and the product retains the strength and compliance of natural material. The invention also provides use of the matrix scaffolds as wound healing material and to investigate tissue structure and function in vitro.

Claims (14)

1. A method of implanting a tissue matrix in bladder reconstruction or replacement surgery comprising:

immersing a distensible membranous sac in a buffer solution at a mild alkaline pH which includes active amounts of a proteolytic inhibitor;

(ii) distending the distensible membranous sac by introducing a sufficient volume of the same buffer solution into the interior cavity of the sac;

(iii) continuing decellularisation of the sac by replacing and introducing fresh solutions around the exterior surface of the sac and/or into the sac interior so as to maintain distension of the sac during recellularisation; and

(iv) implanting the whole decellularised distensible sac or a portion thereof into a donor.

2. The method of claim 1 wherein steps (i) and (ii) are reversed.

3. The method of claim 1 , wherein the distensible membranous sac is a whole bladder.

4. The method of claim 1 , wherein the distensible membranous sac is derived from a pig or a human.

5. A method of urological tissue engineering replacement comprising:

(i) immersing a bladder material in a buffer solution at a mild alkaline pH which includes a proteolytic inhibitor;

(ii) expanding the bladder by introducing a sufficient volume of the same buffer solution into an interior cavity of the bladder so as to stretch and thin the bladder wall; and

(iii) continuing decellularisation of the bladder by replacing and introducing fresh solutions both around the exterior surface of the bladder and into the bladder interior itself so as to maintain expansion of the bladder during decellularisation and to maintain the histoarchitecture of the bladder material; and

(iv) implanting the bladder material or a portion thereof into a donor,

wherein the method of tissue engineering replacement or tissue repair is selected from the group consisting of cosmetic surgery and scaffold for tissue-engineering.

Assignments (2)
SECURITY INTEREST (REVOLVING) Recorded Jun 6, 2019
From: CELLRIGHT TECHNOLOGIES, LLC; TISSUE REGENIX WOUND CARE INC.; TISSUE REGENIX GROUP PLC; TISSUE REGENIX LIMITED
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 049389/0717 →
SECURITY INTEREST (TERM) Recorded Jun 6, 2019
From: CELLRIGHT TECHNOLOGIES, LLC; TISSUE REGENIX WOUND CARE INC.; TISSUE REGENIX GROUP PLC; TISSUE REGENIX LIMITED
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 049389/0732 →
Priority Claims (1)
GB 0606231.9 · Mar 29, 2006 · national
Continuity (2)
Division 12295190
Related Publication 20150050359A1 · Feb 19, 2015